






In the format provided by the authors and unedited.

# An artificial intelligence decision support system for the management of type 1 diabetes

Nichole S. Tyler<sup>1</sup>  , Clara M. Mosquera-Lopez<sup>1</sup>, Leah M. Wilson<sup>2</sup> , Robert H. Dodier<sup>1</sup>, Deborah L. Branigan<sup>2</sup>, Virginia B. Gabo<sup>2</sup>, Florian H. Guillot<sup>2</sup>, Wade W. Hilts<sup>1</sup>, Joseph El Youssef<sup>2</sup>, Jessica R. Castle<sup>2</sup> and Peter G. Jacobs<sup>1</sup>  

---

<sup>1</sup>Artificial Intelligence for Medical Systems (AIMS) Lab, Oregon Health & Science University, Portland, OR, USA. <sup>2</sup>Harold Schnitzer Diabetes Health Center, Oregon Health & Science University, Portland, OR, USA. ✉e-mail: [tylern@ohsu.edu](mailto:tylern@ohsu.edu); [jacobsp@ohsu.edu](mailto:jacobsp@ohsu.edu)

**Supplementary Table 1| Description of real-world human datasets used for KNN-DSS engine evaluation.**

<b>Dataset name</b>	<b>Purpose of dataset use and analysis</b>	<b>Description of data</b>	<b>Study details</b>
<b>Study 1</b>	To compute agreement between KNN-DSS recommendations and endocrinologist recommendations	Continuous glucose monitor Bluetooth-enabled insulin pen Activity monitor device Exercise activity log Meal content and size User adherence to bolus calculations	<i>Participants:</i> 25 adults with type 1 diabetes who undergo multiple daily injection therapy.  <i>Design:</i> Subjects participated in a 28-day study of multiple injection therapy to evaluate a new mobile app interface and collect data reflecting CGM-augmented MDI therapy. Physicians individually reviewed data from separate participants on a weekly basis and recommended changes to insulin therapy. Fifteen of the participants were given physician-reviewed recommendations provided by the KNN-DSS.
<b>Study 2</b>	To compute inter-physician variability in recommendations	Continuous glucose monitor Insulin pump infusion rate Insulin bolus calculations Activity monitor device Exercise announcements Meal content Retrospective physician recommendations for insulin titration	<i>Cited:</i> Reddy et. al <sup>30</sup>  <i>Participants:</i> 10 adults with type 1 diabetes undergoing open-loop insulin pump therapy.  <i>Design:</i> Subjects participated in a 30-day study evaluating overnight glycemic response to aerobic and anaerobic exercise. Following completion of the study, a group of physicians individually and collectively reviewed the all participant data and identified recommended changes to insulin therapy.

---

<b>Study 3</b>	To design real-world meal scenarios to evaluate use of the KNN-DSS <i>in silico</i>	Meal scenarios including carbohydrate content and time of consumption	<p><i>Cited:</i> Castle et. al<sup>31</sup></p> <p><i>Participants:</i> 20 adults with type 1 diabetes undergoing open-loop insulin pump therapy.</p> <p><i>Design:</i> Subjects participated a 4-arm study evaluating closed-loop automated insulin delivery algorithms. Each arm of the study lasted 4 days. Participant recorded meal scenarios and rescue carbs throughout the study.</p>
----------------	---	---	---

---

**Supplementary Table 2| Agreement of recommendations delivered by individual endocrinologists.**

Recommendation Comparison	% Agreement	% Disagreement	% Additional	% Not comparable
<i>Calculated Agreement between Endocrinologists using Real-world Human Data</i>				
<b>Assessing agreement between individual physicians</b>	<i>Full</i> 41.2 <u><i>Partial</i> 14.7</u> Overall <b>55.9</b>	<i>Full</i> 0.3 <u><i>Partial</i> 2.8</u> Overall <b>3.1</b>	<b>32.6</b>	<b>8.4</b>
<b>Assessing agreement between physicians and a consensus recommendation</b>	<i>Full</i> 63.3 <u><i>Partial</i> 6.8</u> Overall <b>70.1</b>	<i>Full</i> 0.1 <u><i>Partial</i> 0.6</u> Overall <b>0.7</b>	<b>24.1</b>	<b>5.1</b>

Agreement is calculated using the Sorenson-Dice coefficient similarity between physician recommendations for each segment of participant data (Equation 6).

**Supplementary Table 3| Evaluation of KNN-DSS *in silico*.**

<i>In silico</i> Evaluation				
OHSU Simulator (N = 29)	Baseline	Week 4	Week 12	End of Study
<b>% time-in-range</b> ( <i>p</i> -value, <i>d</i> = effect size, <i>CI</i> = confidence interval)	59.5% ± 22.8	68.6 ± 17.2% ( <i>p</i> =2E-3, <i>d</i> = 0.64, <i>CI</i> = [3.7,14.5])	79.8 ± 7.3% ( <i>p</i> =2E-5, <i>d</i> = 0.96, <i>CI</i> = [12.3,28.4])	81.1 ± 6.8% ( <i>p</i> =9E-6, <i>d</i> = 1.01, <i>CI</i> = [13.4,29.8])
<b>% time-in-hypoglycemia</b>	0.74 [0.04, 2.88] %	0.69 [0.50, 1.35]% ( <i>p</i> = 0.24, <i>d</i> = 0.41)	1.14 [0.63, 1.41]% ( <i>p</i> = 0.79, <i>d</i> = 0.28)	0.89 [0.66, 1.35]% ( <i>p</i> = 0.69, <i>d</i> = 0.32)
UVA Simulator (N = 100)	Baseline	Week 4	Week 12	End of Study
<b>% time-in-range</b>	75.1% ± 16.1	77.2% ± 17.6 ( <i>p</i> = 2E-1, <i>d</i> = 0.14, <i>CI</i> = [-0.7,5.0])	79.6% ± 15.4 ( <i>p</i> = 1E-2, <i>d</i> = 0.25, <i>CI</i> = [0.9,8.0])	81.8% ± 13.9 ( <i>p</i> = 1E-4, <i>d</i> = 0.39, <i>CI</i> = [3.3,9.9])
<b>% time-in-hypoglycemia</b>	4.0 [1.1, 13.9] %	1.22 [0, 2.2] % ( <i>p</i> =1E-12, <i>d</i> = 0.79)	0.79 [0, 1.6] % ( <i>p</i> =2E-12, <i>d</i> = 0.78)	0.55 [0, 1.2] % ( <i>p</i> =2E-12, <i>d</i> = 0.81)

Simulation of engine use was performed using two virtual patient populations with outcomes determined at weeks 1, 4, 12, and the end of the virtual study. Target range is defined as glucose measured between 70-180 mg dL<sup>-1</sup>. Effect sizes larger than *d* = 0.5 are considered moderate, while effect sizes greater than *d* = 0.8 are considered substantial. Degrees of freedom in statistical tests are *df* = 99 and *df* = 28 for the UVA simulator and OHSU T1D simulator, respectively. A students two-tailed, paired t-test of  $\alpha = 0.05$  was used to compare percent time-in-range from the start of the study to week 4, 12, and study completion. A two-tailed Wilcoxon signed-rank test was used to compare percent time-in-hypoglycemia from the start of the study to week 4, 12, and study completion.

**Supplementary Table 4 | Imposed errors in insulin dosing.**

<b>Insulin Dosing Scenario</b>	<b>Implementation</b>
<b>No Dosing Error</b>	No change to user settings
<b>Postprandial Hypoglycemia</b>	Dosing 20% more insulin than recommended
<b>Severe Postprandial Hypoglycemia</b>	Dosing 40% more insulin than recommended
<b>Postprandial Hyperglycemia</b>	Dosing 20% less insulin than recommended
<b>Severe Postprandial Hyperglycemia</b>	Dosing 40% less insulin than recommended
<b>Aggressive Basal</b>	Dosing 40% more basal than recommended
<b>Insufficient Basal</b>	Dosing 40% less basal than recommended
<b>Aggressive Basal and Insufficient Bolus</b>	Dosing 40% more basal than recommended, and 40% less meal bolus than recommended
<b>Aggressive Basal with Aggressive Bolus</b>	Dosing 40% more basal than recommended, and 40% more meal bolus than recommended
<b>Insufficient Basal with Insufficient Bolus</b>	Dosing 40% less basal than recommended, and 40% less meal bolus than recommended
<b>Insufficient Basal with Aggressive Bolus</b>	Dosing 40% less basal than recommended, and 40% more meal bolus than recommended
<b>Insufficient Basal with Aggressive Correction Bolus</b>	Dosing 40% less basal than recommended, and 40% more correction bolus than recommended
<b>Insufficient Basal with Insufficient Correction Bolus</b>	Dosing 40% less basal than recommended, and 40% less correction bolus than recommended
<b>Adherence to bolus calculators *</b>	Dosing less than or more than indicated by the bolus calculator, by a value of 30%.

\* indicates that the imposed error was not used during training-set generation, but was used during KNN-DSS engine validation.

**Supplementary Table 5| Results of in silico validation using the UVA-Padova simulator.**

<i>In silico</i> Evaluation				
ADULTS UVA Simulator (N = 100)	Baseline	Week 4	Week 12	End of Study
% time-in-range ( <i>p-value</i> , <i>d</i> = effect size, <i>CI</i> = confidence interval)	75.1% ± 16.1	77.2% ± 17.6 ( <i>p</i> = 2E-1, <i>d</i> = 0.14, <i>CI</i> = [-0.7,5.0])	79.6% ± 15.4 ( <i>p</i> = 1E-2, <i>d</i> = 0.25, <i>CI</i> = [0.9,8.0])	81.8% ± 13.9 ( <i>p</i> = 1E-4, <i>d</i> = 0.39, <i>CI</i> = [3.3,9.9])
% time-in-hypoglycemia	4.0 [1.1, 13.9]	1.22 [0,2.2] ( <i>p</i> = 1E-12, <i>d</i> = 0.79)	0.79 [0,1.6] ( <i>p</i> = 2E-12, <i>d</i> = 0.78)	0.55 [0,1.2] ( <i>p</i> = 2E-12, <i>d</i> = 0.81)
ADOLESCENTS UVA Simulator (N = 100)	Baseline	Week 4	Week 12	End of Study
% time-in-range ( <i>p-value</i> , <i>d</i> = effect size, <i>CI</i> = confidence interval)	68.2 ± 13.2	73.9 ± 12.7 ( <i>p</i> = 2E-12, <i>d</i> = .80, <i>CI</i> = [4.3, 7.1])	75.2 ± 12.2 ( <i>p</i> = 8E-9, <i>d</i> = 0.63, <i>CI</i> = [4.8, 9.2])	77.4 ± 12.9 ( <i>p</i> = 2E-10, <i>d</i> = 0.71, <i>CI</i> = [6.6,11.7])
% time-in-hypoglycemia	6.27 [1.7,12.1]	2.31 [1.0,4.1] ( <i>p</i> = 3E-13, <i>d</i> = 0.85)	2.03 [0.8,3.5] ( <i>p</i> = 4E-11, <i>d</i> = 0.75)	2.08 [1.1,3.4] ( <i>p</i> = 9E-12, <i>d</i> = 0.76)
PEDIATRIC UVA Simulator (N = 99*)	Baseline	Week 4	Week 12	End of Study
% time-in-range ( <i>p-value</i> , <i>d</i> = effect size, <i>CI</i> = confidence interval)	65.7% ± 16.9	69.4% ± 16.0 ( <i>p</i> = 2E-4, <i>d</i> = 0.38, <i>CI</i> = [1.8,5.5])	69.1% ± 15.4 ( <i>p</i> = 2E-2, <i>d</i> = 0.24, <i>CI</i> = [0.6,6.2])	71.6% ± 16.3 ( <i>p</i> = 5E-4, <i>d</i> = 0.36, <i>CI</i> = [2.6,9.1])
% time-in-hypoglycemia	4.12 [1.5,9.7]	2.48 [1.1,4.2] ( <i>p</i> = 1E-7, <i>d</i> = 0.58)	2.03 [1.0,3.4] ( <i>p</i> = 1E-7, <i>d</i> = 0.59)	2.13 [1.1,3.4] ( <i>p</i> = 7E-8, <i>d</i> = 0.59)

\* indicates one subject was excluded due to computational errors in the simulation. Simulation of engine use was performed with outcomes determined at weeks 1, 4, 12, and the end of the virtual study. Target range is defined as glucose measured between 70-180 mg dL<sup>-1</sup>. Effect sizes larger than *d* = 0.5 are considered moderate, while effect sizes greater than *d* = 0.8 are considered substantial. A students two-tailed, paired t-test of alpha = 0.05 was used to compare percent time-in-range from the start of the study to week 4, 12, and study completion. A two-tailed Wilcoxon signed-rank test was used to compare percent time-in-hypoglycemia from the start of the study to week 4, 12, and study completion.

**Supplementary Table 6| Top 5 features for each class of recommendations delivered by the K-nearest-neighbors algorithm, as ranked by mutual information criteria calculation.**

<b>Recommendation</b>	<b>Top 5 Features</b>
<b>Decrease Basal Insulin</b>	Percent Time-in-Hypoglycemia Frequency of Hypoglycemic Events Nocturnal Hypoglycemia Percent Time-in-Hyperglycemia Postprandial Hypoglycemia, Overnight
<b>Increase Basal Insulin</b>	Frequency of Hypoglycemic Events Percent Time-in-Hyperglycemia Percent Time-in-Hypoglycemia Nocturnal Hypoglycemia Postprandial Hypoglycemia, Overnight
<b>Increase Meal Bolus Dosed 7AM-11AM</b>	Percent Time-in-Hyperglycemia Percent Time-in-Serious-Hyperglycemia Postprandial Hyperglycemia, 3PM-8PM Percent Time-in-Hypoglycemia Postprandial Serious Hyperglycemia, 3PM-8PM
<b>Increase Meal Bolus Dosed 11AM-3PM</b>	Percent Time-in-Hyperglycemia Percent Time-in-Serious-Hyperglycemia Percent Time-in-Hypoglycemia Postprandial Hypoglycemia, 3PM-8PM Frequency of Hypoglycemic Events
<b>Increase Meal Bolus Dosed 3PM-8PM</b>	Percent Time-in-Hyperglycemia Postprandial Hyperglycemia, 3PM-8PM Postprandial Hypoglycemia, Overnight Frequency of Hypoglycemic Events Percent Time-in-Hypoglycemia
<b>Increase Meal Bolus Dosed Overnight</b>	Percent Time-in-Hyperglycemia Percent Time-in-Serious-Hyperglycemia Postprandial Serious Hyperglycemia, 3PM-8PM



	Correction Boluses
	Postprandial Serious Hyperglycemia, 3PM-8PM
<b>Decrease Meal Bolus Dosed 7AM-11AM</b>	Postprandial Hypoglycemia, 11AM-3PM Postprandial Hypoglycemia, 7AM-11AM Frequency of Serious Hypoglycemic Events Postprandial Serious Hypoglycemia, 11AM-3PM Postprandial Serious Hypoglycemia, 7AM-11AM
<b>Decrease Meal Bolus Dosed 11AM-3PM</b>	Postprandial Hypoglycemia, 3PM-8PM Percent Time-in-Hypoglycemia Frequency of Hypoglycemic Events Frequency of Serious Hypoglycemic Events Postprandial Hypoglycemia, 11AM-3PM
<b>Decrease Meal Bolus Dosed 3PM-8PM</b>	Postprandial Serious Hypoglycemia, Overnight Postprandial Hypoglycemia, Overnight Frequency of Serious Hypoglycemic Events Percent Time-in-Hypoglycemia Frequency of Hypoglycemic Events
<b>Decrease Meal Bolus Dosed Overnight</b>	Percent Time-in-Hypoglycemia Frequency of Hypoglycemic Events Nocturnal Hypoglycemia Postprandial Hypoglycemia, Overnight Frequency of Serious Hypoglycemic Events

The recommendation to decrease basal insulin was most closely related to frequency and duration of hypoglycemia as well as nighttime glycemic excursions. The recommendation to decrease meal bolus aggressiveness was most closely related to the person's postprandial hypoglycemia. The recommendation to increase insulin before meals was most closely related to serious hyperglycemic events and overall daytime glycemic excursions. The relationship of these specific glycemic features with their associated optimal recommendations matches intuition and, in general, is synonymous with physician opinions regarding titration of insulin dosing for people with T1D.

**Supplementary Table 7| Glycemic features selected as inputs into the KNN-DSS lookup table.**

<b>Feature</b>	<b>Description</b>	<b>Normalization</b>
<b>Frequency of Hypoglycemic events</b>	Overall number of independent hypoglycemic events detected in the users CGM data. Data is converted to a frequency measurement (# hypoglycemic events per # days of data).	Normalized to the expected frequency of hypoglycemic events for people with T1D (1.16 hypoglycemic events per day, a value determined from a separate dataset <sup>30</sup> ).
<b>Nocturnal Hypoglycemia</b>	Number of hypoglycemic events detected between 10PM-7AM, normalized to the overall number of independent hypoglycemic events detected in the users CGM data.	“
<b>Abnormal Morning Hypoglycemia</b>	Number of abnormal morning hypoglycemic events detected in the user CGM data. Data is normalized to overall number of hypoglycemic events detected in the users CGM data.	“
<b>Postprandial Hypoglycemia 7AM – 11AM</b>	Number of hypoglycemic events detected following a meal bolus dosed between 7AM-11AM. Data is then normalized to the overall number of hypoglycemic events detected in the users CGM data.	“
<b>Postprandial Hypoglycemia 11AM – 3PM</b>	Number of hypoglycemic events detected following a meal bolus dosed between 11AM – 3 PM. Data is then normalized to the overall number of hypoglycemic events detected in the users CGM data.	“
<b>Postprandial Hypoglycemia 3PM – 8PM</b>	Number of hypoglycemic events detected following a meal bolus dosed between 3PM – 8PM. Data is then normalized to the overall number of hypoglycemic events detected in the users CGM data.	“
<b>Postprandial Hypoglycemia Overnight</b>	Number of hypoglycemic events detected following a meal bolus dosed between 8PM – 7AM. Data is then normalized to the overall number of hypoglycemic events detected in the users CGM data.	“
<b>Correction-Related Hypoglycemia</b>	Number of hypoglycemic events detected following correction boluses dosed. Data is normalized to the overall number of	“

	hypoglycemic events detected in the users CGM data.	
<b>Frequency of Serious Hypoglycemic events</b>	Overall number of independent serious hypoglycemic events detected in the users CGM data. Data is converted to a frequency measurement (# serious hypoglycemic events / # days of data).	“
<b>Serious Postprandial Hypoglycemia 7AM – 11AM</b>	Number of serious hypoglycemic events detected following a meal bolus dosed between 7AM-11AM. Data is then normalized to the overall number of hypoglycemic events detected in the users CGM data.	“
<b>Serious Postprandial Hypoglycemia 11AM – 3PM</b>	Number of serious hypoglycemic events detected following a meal bolus dosed between 11AM-3PM. Data is then normalized to the overall number of hypoglycemic events detected in the users CGM data.	“
<b>Serious Postprandial Hypoglycemia 3PM – 8PM</b>	Number of serious hypoglycemic events detected following a meal bolus dosed between 3PM-8PM. Data is then normalized to the overall number of hypoglycemic events detected in the users CGM data.	“
<b>Serious Postprandial Hypoglycemia Nighttime</b>	Number of serious hypoglycemic events detected following a meal bolus dosed between 8PM-7AM. Data is then normalized to the overall number of hypoglycemic events detected in the users CGM data.	“
<b>Correction-Related Serious Hypoglycemia</b>	Number of serious hypoglycemic events detected following correction boluses dosed. Data is normalized to the overall number of hypoglycemic events detected in the users CGM data.	“
<b>Percent Time-in-Hypoglycemia</b>	The percent of time that the users CGM measured less than 70 mg/dL.	N/A
<b>Postprandial Hyperglycemia 3PM-8PM</b>	Number of hyperglycemic events detected following a meal bolus dosed between 3PM-8PM. Data is then normalized to the overall number of hyperglycemic events detected in the users CGM data.	Normalized to the expected frequency of hyperglycemic events for people with T1D (2.05 hyperglycemic events per day, a

		value determined from a separate dataset <sup>30</sup> ).
<b>Correction Related Hyper</b>	Number of hyperglycemic events detected following correction boluses dosed. Data is normalized to the overall number of hyperglycemic events detected in the users CGM data.	“
<b>Serious Postprandial Hyper 7AM – 11AM</b>	Number of serious hyperglycemic events detected following a meal bolus dosed between 7AM-11AM. Data is then normalized to the overall number of hyperglycemic events detected in the users CGM data.	“
<b>Serious Postprandial Hyper 11AM – 3PM</b>	Number of serious hyperglycemic events detected following a meal bolus dosed between 11AM-3PM. Data is then normalized to the overall number of hyperglycemic events detected in the users CGM data.	“
<b>Serious Postprandial Hyper 3PM – 8PM</b>	Number of serious hyperglycemic events detected following a meal bolus dosed between 3PM-8PM. Data is then normalized to the overall number of hyperglycemic events detected in the users CGM data.	“
<b>Serious Postprandial Hyper Overnight</b>	Number of serious hyperglycemic events detected following a meal bolus dosed between 8PM-7AM. Data is then normalized to the overall number of hyperglycemic events detected in the users CGM data.	“
<b>Correction Related Serious Hyperglycemia</b>	Number of serious hyperglycemic events detected following correction boluses dosed. Data is normalized to the overall number of hyperglycemic events detected in the users CGM data.	“
<b>Percent Time in Hyperglycemia</b>	The percent of time that the users CGM measured greater than 180 mg/dL	N/A
<b>Percent Time in Serious Hyperglycemia</b>	The percent of time that the users CGM measured greater than 300 mg/dL	N/A

<b>Correction Boluses</b>	Number of detected correction boluses dosed.	Normalized to the expected maximum number of correction boluses based on treatment recommendations (8 doses per 24hr period if users dosed once / three hours)
---------------------------	--	--

Hypoglycemia is defined as measured glucose  $< 70 \text{ mg dL}^{-1}$ , serious hypoglycemia is defined as measured glucose  $< 54 \text{ mg dL}^{-1}$ , hyperglycemia is defined as glucose  $> 180 \text{ mg dL}^{-1}$ , and serious hyperglycemia is defined as glucose  $> 300 \text{ mg dL}^{-1}$ . To count an individual hypoglycemic or hyperglycemic event, measured glucose must be within the specified range and preceded by 20 continuous minutes of euglycemia; this hysteresis approach is used to prevent over-counting glycemic events that occurred due to CGM measurement noise.

**Supplementary Table 8 | Look-up table class representation.**

<b>Recommendation</b>	<b>Count</b>	<b>Percent</b>
<b>Increase Basal</b>	3723	7.18%
<b>Decrease Basal</b>	12041	23.23%
<b>Increase AM Bolus</b>	2574	4.97%
<b>Increase PM Bolus</b>	2549	4.92%
<b>Increase Evening Bolus</b>	3185	6.14%
<b>Increase Overnight Bolus</b>	1046	2.02%
<b>Decrease AM Bolus</b>	3744	7.22%
<b>Decrease PM Bolus</b>	4678	9.03%
<b>Decrease Evening Bolus</b>	7064	13.63%
<b>Decrease Overnight Bolus</b>	1565	3.02%
<b>No Adjustment Recommended</b>	9662	18.64%

**Supplementary Table 9 | Classification accuracy for weighting schemes.**

<b>K-nearest-neighbors classification weighting</b>	<b>% Classification Accuracy</b>
<b>No weighting imposed</b>	0.6886
<b>Class and distance-based weighting</b>	0.7385
<b>Distance-based weighting</b>	0.7221
<b>Class-based weighting</b>	0.6864

**Supplementary Table 10| Criteria used for labeling a recommendation from the KNN-DSS as in full agreement, partial agreement, full disagreement, or partial disagreement with a physician.**

<b>KNN-DSS Recommendation</b>	<b>Physician Recommendation</b>			
	<i>Full Agreement</i>	<i>Partial Agreement</i>	<i>Full Disagreement</i>	<i>Partial Disagreement</i>
<b>Increase Basal Insulin</b>	Increase Basal Insulin	Increase short-acting insulin doses for meals or corrections	Decrease basal insulin	Decrease short-acting insulin doses for meals or corrections
<b>Decrease Basal Insulin</b>	Decrease basal insulin	Decrease short-acting insulin doses for meals or corrections	Increase Basal Insulin	Increase short-acting insulin doses for meals or corrections
<b>Increase Meal Insulin, AM</b>	Increase meal insulin AM	Increase meal or correction insulin (in adjacent time windows overnight and afternoon)  Increase basal insulin  Adhere to bolus calculator or basal dosage.	Decrease meal insulin AM.	Decrease meal or correction insulin (in adjacent time windows overnight and afternoon)  Increase or decrease meal or correction insulin (non-adjacent time window evening)  Decrease basal insulin
<b>Increase Meal Insulin, Afternoon</b>	Increase meal insulin afternoon	Increase meal or correction insulin (in adjacent time windows AM and evening)  Increase basal insulin  Adhere to bolus calculator or basal dosage	Decrease meal insulin afternoon.	Decrease meal or correction insulin (in adjacent time windows AM and evening)  Increase or decrease meal or correction insulin (non-adjacent time window overnight)  Decrease basal insulin
<b>Increase Meal Insulin, Evening</b>	Increase meal insulin evening	Increase meal or correction insulin (in adjacent time windows afternoon and overnight)  Increase basal insulin  Adhere to bolus calculator or basal dosage.	Decrease meal insulin evening	Decrease meal or correction insulin (in adjacent time windows afternoon and overnight)  Increase or decrease meal or correction insulin (non-adjacent time window AM)  Decrease basal insulin
<b>Increase Meal Insulin, Overnight</b>	Increase meal insulin overnight	Increase meal or correction insulin (in adjacent time windows evening and AM)  Increase basal insulin	Decrease meal insulin overnight	Decrease meal or correction insulin (in adjacent time windows evening and AM)  Increase or decrease meal or correction



		Adhere to bolus calculator or basal dosage		insulin (non-adjacent time window afternoon) Decrease basal insulin
<b>Decrease Meal Insulin, AM</b>	Decrease meal insulin AM	Decrease meal or correction insulin (in adjacent time windows overnight and afternoon) Decrease basal insulin Adhere to bolus calculator or basal dosage	Increase meal insulin AM Partial disagreement	Increase meal or correction insulin (in adjacent time windows overnight and afternoon) Increase or decrease meal or correction insulin (non-adjacent time window evening) Increase basal insulin
<b>Decrease Meal Insulin, Afternoon</b>	Decrease meal insulin afternoon	Decrease meal or correction insulin (in adjacent time windows AM and evening) Decrease basal insulin Adhere to bolus calculator or basal dosage	Increase meal insulin afternoon	Increase meal or correction insulin (in adjacent time windows AM and evening) Increase or decrease meal or correction insulin (non-adjacent time window overnight) Increase basal insulin
<b>Decrease Meal Insulin, Evening</b>	Decrease meal insulin evening	Decrease meal or correction insulin (in adjacent time windows afternoon and overnight) Decrease basal insulin Adhere to bolus calculator or basal dosage	Increase meal insulin evening	Increase meal or correction insulin (in adjacent time windows afternoon and overnight) Increase or decrease meal or correction insulin (non-adjacent time window AM) Increase basal insulin
<b>Decrease Meal Insulin, Overnight</b>	Decrease meal insulin overnight	Decrease meal or correction insulin (in adjacent time windows evening and AM) Decrease basal insulin Adhere to bolus calculator or basal dosage	Increase meal insulin overnight	Increase meal or correction insulin (in adjacent time windows evening and AM) Increase or decrease meal or correction insulin (non-adjacent time window afternoon) Increase basal insulin
<b>Increase Correction Insulin, AM</b>	Increase correction insulin AM	Increase meal or correction insulin (in adjacent time windows overnight and afternoon) Increase basal insulin Adhere to bolus calculator or basal dosage	Decrease correction insulin AM	Decrease meal or correction insulin (in adjacent time windows overnight and afternoon) Increase or decrease meal or correction insulin (non-adjacent time window evening)

				Decrease basal insulin
<b>Increase Correction Insulin, Afternoon</b>	Increase correction insulin afternoon	Increase meal or correction insulin (in adjacent time windows AM and evening)  Increase basal insulin  Adhere to bolus calculator or basal dosage	Decrease correction insulin afternoon	Decrease meal or correction insulin (in adjacent time windows AM and evening)  Increase or decrease meal or correction insulin (non-adjacent time window overnight)  Decrease basal insulin
<b>Increase Correction Insulin, Evening</b>	Increase correction insulin evening	Increase meal or correction insulin (in adjacent time windows afternoon and overnight)  Increase basal insulin  Adhere to bolus calculator or basal dosage	Decrease correction insulin evening	Decrease meal or correction insulin (in adjacent time windows afternoon and overnight)  Increase or decrease meal or correction insulin (non-adjacent time window AM)  Decrease basal insulin
<b>Increase Correction Insulin, Overnight</b>	Increase correction insulin overnight	Increase meal or correction insulin (in adjacent time windows evening and AM)  Increase basal insulin  Adhere to bolus calculator or basal dosage	Decrease correction insulin overnight	Decrease meal or correction insulin (in adjacent time windows evening and AM)  Increase or decrease meal or correction insulin (non-adjacent time window afternoon)  Decrease basal insulin
<b>Decrease Correction Insulin, AM</b>	Decrease correction insulin AM	Decrease meal or correction insulin (in adjacent time windows overnight and afternoon)  Decrease basal insulin  Adhere to bolus calculator or basal dosage	Increase correction insulin AM	Increase meal or correction insulin (in adjacent time windows overnight and afternoon)  Increase or decrease meal or correction insulin (non-adjacent time window evening)  Increase basal insulin
<b>Decrease Correction Insulin, Afternoon</b>	Decrease correction insulin afternoon	Decrease meal or correction insulin (in adjacent time windows AM and evening)  Decrease basal insulin  Adhere to bolus calculator or basal dosage	Increase correction insulin afternoon	Increase meal or correction insulin (in adjacent time windows AM and evening)  Increase or decrease meal or correction insulin (non-adjacent time window overnight)  Increase basal insulin

<b>Decrease Correction Insulin, Evening</b>	Decrease correction insulin evening	Decrease meal or correction insulin (in adjacent time windows afternoon and overnight)  Decrease basal insulin  Adhere to bolus calculator or basal dosage	Increase correction insulin evening	Increase meal or correction insulin (in adjacent time windows afternoon and overnight)  Increase or decrease meal or correction insulin (non-adjacent time window AM)  Increase basal insulin
<b>Decrease Correction Insulin, Overnight</b>	Decrease correction insulin overnight	Decrease meal or correction insulin (in adjacent time windows evening and AM)  Decrease basal insulin  Adhere to bolus calculator or basal dosage	Increase correction insulin overnight	Increase meal or correction insulin (in adjacent time windows evening and AM)  Increase or decrease meal or correction insulin (non-adjacent time window afternoon)  Increase basal insulin
<b>No change to settings</b>	No change to settings	N/A	N/A	N/A
<b>Use bolus calculator</b>	Use the bolus calculator	Modify short-acting bolus	N/A	N/A
<b>Adhere to basal insulin dosage</b>	Adhere to basal insulin dosage	Modify basal dosage	N/A	N/A

Additional: No change to settings indicated. As an example, for each unique recommendation delivered by Party A, we define subsets of recommendations corresponding to the categories *perfect agreement*, *partial agreement*, *disagreement*, and *partial disagreement*. We then calculate the similarity between these subsets and the recommendations delivered by Party B. This determines the agreement between Party A and Party B with respect to perfect agreement, partial agreement, disagreement, and partial disagreement.